Overview CLARITY-AD (NCT03887455) was a landmark Phase 3 randomized, double-blind, placebo-controlled trial evaluating lecanemab (Leqembi) in early Alzheimer's disease patients. The trial met its primary endpoint, demonstrating statistically significant slowing of cognitive decline and represents the first Phase 3 trial of an anti-amyloid antibody to show clear clinical benefit in early AD[@lecanemab2023].
Lecanemab received accelerated approval from the FDA in January 2023 based on the CLARITY-AD results, making it the first amyloid-targeting therapy to demonstrate meaningful clinical efficacy in a Phase 3 trial.
Trial Details | Parameter | Value |NCT Number | NCT03887455 |Phase | Phase 3 |Status | Completed |Sponsor | Eisai Co., Ltd. |Collaborator | Biogen |Enrollment | 1,795 patients |Duration | 18 months |Location | Multiple countries worldwide |Drug | Lecanemab (Leqembi) |Dosage | 10 mg/kg biweekly IV infusion |
Mechanism of Action Lecanemab is a monoclonal antibody that selectively binds to and clears soluble amyloid-beta (Aβ) protofibrils, which are believed to be the most toxic form of amyloid plaques in Alzheimer's disease[@lecanemab2023].
Target Specificity
Primary Target : Aβ protofibrils (soluble oligomeric species)Epitope : 3X42 region of AβSelectivity : 100-fold greater affinity for protofibrils vs monomersMechanism : Fc-mediated microglial phagocytosisAmyloid Clearance Pathway ...
Overview CLARITY-AD (NCT03887455) was a landmark Phase 3 randomized, double-blind, placebo-controlled trial evaluating lecanemab (Leqembi) in early Alzheimer's disease patients. The trial met its primary endpoint, demonstrating statistically significant slowing of cognitive decline and represents the first Phase 3 trial of an anti-amyloid antibody to show clear clinical benefit in early AD[@lecanemab2023].
Lecanemab received accelerated approval from the FDA in January 2023 based on the CLARITY-AD results, making it the first amyloid-targeting therapy to demonstrate meaningful clinical efficacy in a Phase 3 trial.
Trial Details | Parameter | Value |NCT Number | NCT03887455 |Phase | Phase 3 |Status | Completed |Sponsor | Eisai Co., Ltd. |Collaborator | Biogen |Enrollment | 1,795 patients |Duration | 18 months |Location | Multiple countries worldwide |Drug | Lecanemab (Leqembi) |Dosage | 10 mg/kg biweekly IV infusion |
Mechanism of Action Lecanemab is a monoclonal antibody that selectively binds to and clears soluble amyloid-beta (Aβ) protofibrils, which are believed to be the most toxic form of amyloid plaques in Alzheimer's disease[@lecanemab2023].
Target Specificity
Primary Target : Aβ protofibrils (soluble oligomeric species)Epitope : 3X42 region of AβSelectivity : 100-fold greater affinity for protofibrils vs monomersMechanism : Fc-mediated microglial phagocytosisAmyloid Clearance Pathway
Binding : Lecanemab binds to Aβ protofibrils in the brainComplex Formation : Antibody-antigen complexes activate Fc receptorsPhagocytosis : Microglia are recruited to clear the complexesPlaque Reduction : Amyloid plaques are progressively removedThis mechanism differs from earlier anti-amyloid antibodies that primarily targeted monomeric Aβ or showed limited brain penetration.
Patient Population The trial enrolled patients meeting strict criteria:
Inclusion Criteria
Diagnosis : Mild Cognitive Impairment (MCI) due to AD or mild AD dementiaAge : 50-90 yearsMMSE score : 22-30Amyloid positive : Confirmed by PET scan or CSF biomarkersCDR score : 0.5-1.0Key Characteristics
Mean age: 71 years
Approximately 50% female
diverse ethnic representation
Early AD stage (MCI or mild dementia)
Endpoints
Primary Endpoint
Measure : Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 monthsResult : -0.45 vs placebo (p=0.00005)Secondary Endpoints | Endpoint | Result | p-value |
Results
Primary Efficacy The trial demonstrated significant clinical benefit:
CDR-SB change : -0.45 vs placebo (27% slowing of progression)Statistical significance : p=0.00005 (highly significant)Clinical meaningfulness : Slowed decline by approximately 4-5 months equivalentAmyloid Reduction
Amyloid PET : 59.1 Centiloid reduction from baselinePlaque removal : Near-complete clearance in most patientsSustained effect : Maintained throughout 18-month treatment periodSubgroup Analyses Consistent benefits observed across:
Age groups (50-90 years)
APOE ε4 carriers and non-carriers
MCI and mild AD dementia subgroups
Various ethnic backgrounds
Adverse Events | Adverse Event | Lecanemab | Placebo |
ARIA Management Amyloid-related imaging abnormalities (ARIA) are managed through:
Routine MRI monitoring
Dose titration at initiation
Careful patient selection
Education of clinicians and caregivers
Most ARIA cases were asymptomatic or mild; serious events were rare[@schilling2024].
Clinical Significance
First Demonstrable Disease Modification CLARITY-AD represents a pivotal moment in Alzheimer's disease research as it demonstrates:
Disease modification : Direct targeting of core pathologyMeaningful clinical benefit : Slower cognitive declineAmyloid-cognition link : Removal of amyloid correlates with clinical benefit
Regulatory Impact The results led to:
FDA traditional approval (July 2023)
Coverage by Medicare in the US
Inclusion in clinical practice guidelines
Real-World Implications For patients with early AD[@cummings2023]:
Earlier diagnosis becomes more critical
Amyloid testing is essential for treatment selection
Monitoring protocols must be implemented
Benefits outweigh risks for appropriate patients
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
[Amyloid-beta](/proteins/amyloid-beta)
[Anti-Amyloid Immunotherapy](/therapeutics/lecanemab)
[Amyloid PET Imaging](/biomarkers/amyloid-pet)
Future Directions and Ongoing Studies
Open-Label Extension The CLARITY-1 (NCT05406091) open-label extension allows patients who completed CLARITY-AD to continue receiving lecanemab, providing:
Long-term safety data
Durability of treatment effect
Insights into extended amyloid clearance
Combination Studies Research is exploring lecanemab in combination with other therapies:
Leqembi + AL002 : Anti-TREM2 antibody combinationLeqembi + E2814 : Anti-tau antibody combinationLeqembi + small molecules : Various mechanismsPrevention Trials The DIAN-TU-001 trial is evaluating lecanemab in autosomal dominant AD, while the A4 study continues in preclinical AD.
Broader Access Programs Eisai has implemented:
Patient assistance programs
Site expansion for infusion capacity
Telehealth for monitoring visits
Related Pages
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Lecanemab](/therapeutics/lecanemab)
[BAN2401 Phase 2b Trial](/clinical-trials/ban2401-201)
[Donanemab TRAILBLAZER-ALZ](/clinical-trials/donanemab-trailblazer-alz2)
[A4 Study](/clinical-trials/a4-study)
References
[van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449427/)
[Cummings J, et al. Lecanemab: The new era of Alzheimer's disease treatment (2023)](https://doi.org/10.1002/alz.13352)
[Reim J, et al. Clinical implications of lecanemab for Alzheimer's disease (2024)](https://doi.org/10.1038/s41582-023-00898-9)
[Schilling LP, et al. Amyloid-related imaging abnormalities with lecanemab (2024)](https://doi.org/10.1038/s41582-024-00841-4)
[ClinicalTrials.gov: NCT03887455](https://clinicaltrials.gov/study/NCT03887455) Show full description